<rss version="2.0"><channel><title>Yahoo! Finance: NVC.TO News</title><copyright>Copyright (c) 2016 Yahoo! Inc. All rights reserved.</copyright><link>http://finance.yahoo.com/q/h?s=nvc.to</link><description>Latest Financial News for NEOVASC INC</description><language>en-US</language><lastBuildDate>Fri, 02 Dec 2016 12:00:00 GMT</lastBuildDate><image><url>http://l.yimg.com/a/i/brand/purplelogo/uh/us/fin.gif</url><title>Yahoo! Finance: NVC.TO News</title><link>http://finance.yahoo.com/q/h?s=nvc.to</link><width>144</width><height>45</height></image><item><title>Neovasc and Boston Scientific Reach US$75 Million Agreement</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/neovasc-boston-scientific-reach-us-120000841.html</link><description>[CNW Group] - Neovasc and Boston Scientific Reach US$75 Million Agreement</description><guid isPermaLink="false">yahoo_finance/1284239949</guid><pubDate>Fri, 02 Dec 2016 12:00:00 GMT</pubDate></item><item><title>Neovasc and Boston Scientific Reach US$75 Million Agreement</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/neovasc-boston-scientific-reach-us-120000849.html</link><description>[PR Newswire] - VANCOUVER, Dec. 2, 2016 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVC.TO) today announced that Boston Scientific Corporation (BSX), a global medical technology leader, has agreed to acquire Neovasc's tissue processing technology and facility for approximately US$67,909,800. Concurrently, Boston Scientific has committed to invest an additional US$7,090,200 in Neovasc for a 15% equity interest in the Company.</description><guid isPermaLink="false">yahoo_finance/1233513445</guid><pubDate>Fri, 02 Dec 2016 12:00:00 GMT</pubDate></item><item><title>Boston Scientific Announces Agreement to Acquire Neovasc Advanced Biological Tissue Capabilities</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/boston-scientific-announces-agreement-acquire-120000893.html</link><description>[PR Newswire] - MARLBOROUGH, Mass., Dec. 2, 2016 /PRNewswire/ -- Boston Scientific Corporation (BSX) today announced a definitive agreement to acquire certain manufacturing assets and capabilities of the Neovasc, Inc., (NVCN) (NVC.TO) advanced biological tissue business, as well as a 15% equity stake in Neovasc, for a total of $75 million in cash. "We continually seek ways to optimize our manufacturing processes and enhance our product portfolio," said Ed Mackey, executive vice president, operations, Boston Scientific. The acquisition is expected to close by year-end 2016, subject to customary closing conditions, and to be immaterial to Boston Scientific earnings per share (EPS) in 2016 and 2017 on an adjusted and GAAP basis.</description><guid isPermaLink="false">yahoo_finance/3347114646</guid><pubDate>Fri, 02 Dec 2016 12:00:00 GMT</pubDate></item><item><title>Neovasc Receives Regulatory Approval to Initiate TIARA II CE Mark Study</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/neovasc-receives-regulatory-approval-initiate-120000018.html</link><description>[CNW Group] - Neovasc Receives Regulatory Approval to Initiate TIARA II CE Mark Study</description><guid isPermaLink="false">yahoo_finance/3247244788</guid><pubDate>Mon, 28 Nov 2016 12:00:00 GMT</pubDate></item><item><title>Neovasc Receives Regulatory Approval to Initiate TIARA II CE Mark Study</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/neovasc-receives-regulatory-approval-initiate-120000300.html</link><description>[PR Newswire] - VANCOUVER, Nov. 28, 2016 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVC.TO) today announced it has received both regulatory and ethics committee approval to initiate the Tiara&#8482; Transcatheter Mitral Valve Replacement Study (TIARA II) in Italy. TIARA II is a 115 patient, non-randomized, prospective clinical study evaluating the safety and performance of the Tiara&#8482; Transcatheter Mitral Valve with the Tiara&#8482; Transapical Delivery System (Tiara&#8482;). With these critical approvals now in place, it is expected that the first Italian TIARA II clinical study site will be initiated before year end, with first enrollment anticipated early in the new year. Approvals in additional geographies are expected in the first quarter of 2017.</description><guid isPermaLink="false">yahoo_finance/334527316</guid><pubDate>Mon, 28 Nov 2016 12:00:00 GMT</pubDate></item><item><title>Neovasc Announces Dismissal of Class Action Lawsuit</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/neovasc-announces-dismissal-class-action-131400128.html</link><description>[PR Newswire] - The Court ruled in favor of the Company and its officers on all claims and ordered the entire case closed. The Company is not aware as to whether, and presently cannot foresee whether, the plaintiff will appeal the dismissal of his claims or will file any post-dismissal motions. Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products in development include the Tiara&#8482;, for the transcatheter treatment of mitral valve disease and the Neovasc Reducer&#8482; for the treatment of refractory angina.</description><guid isPermaLink="false">yahoo_finance/1057794989</guid><pubDate>Wed, 23 Nov 2016 13:14:00 GMT</pubDate></item><item><title>Neovasc Announces Dismissal of Class Action Lawsuit</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/neovasc-announces-dismissal-class-action-131400799.html</link><description>[CNW Group] - Neovasc Announces Dismissal of Class Action Lawsuit</description><guid isPermaLink="false">yahoo_finance/736078663</guid><pubDate>Wed, 23 Nov 2016 13:14:00 GMT</pubDate></item><item><title>Research Reports Initiated on Healthcare Stocks Titan Medical, CRH Medical, Neovasc, and LED Medical Diagnostics</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://news.investornetwork.com/2016/11/21/research-reports-initiated-on-healthcare-stocks-titan-medical-crh-medical-neovasc-and-led-medical-diagnostics/?1=1&amp;1479735998</link><description /><guid isPermaLink="false">yahoo_finance/4245923463</guid><pubDate>Mon, 21 Nov 2016 13:46:38 GMT</pubDate></item><item><title>Neovasc reports 3Q loss</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://sg.finance.yahoo.com/news/neovasc-reports-3q-loss-211746891.html</link><description /><guid isPermaLink="false">yahoo_finance/2538654880</guid><pubDate>Mon, 14 Nov 2016 21:17:46 GMT</pubDate></item><item><title>Neovasc reports 3Q loss</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/neovasc-reports-3q-loss-211746933.html</link><description /><guid isPermaLink="false">yahoo_finance/3984830965</guid><pubDate>Mon, 14 Nov 2016 21:17:46 GMT</pubDate></item><item><title>Neovasc Reports Third Quarter Results for 2016</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/neovasc-reports-third-quarter-results-210000917.html</link><description>[CNW Group] - Neovasc Reports Third Quarter Results for 2016</description><guid isPermaLink="false">yahoo_finance/2536474934</guid><pubDate>Mon, 14 Nov 2016 21:00:00 GMT</pubDate></item><item><title>Neovasc Reports Third Quarter Results for 2016</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/neovasc-reports-third-quarter-results-210000445.html</link><description>[PR Newswire] - NASDAQ: NVCN TSX: NVC VANCOUVER, Nov. 14, 2016 /PRNewswire/ - Neovasc Inc. (" Neovasc " or the " Company ") (NASDAQ: NVCN) (TSX: NVC) today announced financial results for the quarter ...</description><guid isPermaLink="false">yahoo_finance/4294484370</guid><pubDate>Mon, 14 Nov 2016 21:00:00 GMT</pubDate></item><item><title>Q3 2016 Neovasc Inc Earnings Release - After Market Close</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/research/earncal/20161114.html?t=nvc.to</link><description /><guid isPermaLink="false">yahoo_finance/2157506090</guid><pubDate>Mon, 14 Nov 2016 12:07:02 GMT</pubDate></item><item><title>Neovasc to Host Third Quarter 2016 Conference Call</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/neovasc-host-third-quarter-2016-214200087.html</link><description>[PR Newswire] - NASDAQ: NVCN TSX: NVC VANCOUVER, Nov. 7, 2016 /PRNewswire/ - Neovasc Inc. (" Neovasc " or the " Company ") (NASDAQ: NVCN) (TSX: NVC) today announced that it will release its financial ...</description><guid isPermaLink="false">yahoo_finance/3866332876</guid><pubDate>Mon, 07 Nov 2016 21:42:00 GMT</pubDate></item><item><title>Neovasc to Host Third Quarter 2016 Conference Call</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/neovasc-host-third-quarter-2016-214200156.html</link><description>[CNW Group] - Neovasc to Host Third Quarter 2016 Conference Call</description><guid isPermaLink="false">yahoo_finance/881263569</guid><pubDate>Mon, 07 Nov 2016 21:42:00 GMT</pubDate></item><item><title>Neovasc's Tiara and Reducer Highlighted at TCT Presentations</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/neovascs-tiara-reducer-highlighted-tct-110000113.html</link><description>[CNW Group] - Neovasc's Tiara and Reducer Highlighted at TCT Presentations</description><guid isPermaLink="false">yahoo_finance/780564571</guid><pubDate>Wed, 02 Nov 2016 11:00:00 GMT</pubDate></item><item><title>Neovasc's Tiara and Reducer Highlighted at TCT Presentations</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/neovascs-tiara-reducer-highlighted-tct-110000585.html</link><description>[PR Newswire] - On October 31, Dr. Anson Cheung from St. Paul's hospital, Vancouver, Canada presented an update on the ongoing Tiara&#8482; program. The TIARA-I trial is assessing the safety and performance of the Tiara&#8482; mitral valve system and the implantation procedure in high-risk patients suffering from severe mitral regurgitation. With respect to the Company's other cardiovascular device, the Neovasc Reducer&#8482;, for the treatment of Refractory Angina, Dr. Gregg Stone presented the Reducer as the most effective treatment option for patients suffering from refractory angina despite optimal medical therapy. He reviewed the results of the COSIRA randomized study which was published in the New England Journal of Medicine last year. He also outlined the design of the COSIRA II, pivotal US trial, which will include 380 patients and will be a multicenter prospective, randomized, double-blind, sham-controlled trial.</description><guid isPermaLink="false">yahoo_finance/4280169304</guid><pubDate>Wed, 02 Nov 2016 11:00:00 GMT</pubDate></item><item><title>IIROC Trade Resumption - NVC</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/iiroc-trade-resumption-nvc-120900334.html</link><description /><guid isPermaLink="false">yahoo_finance/3274690601</guid><pubDate>Tue, 01 Nov 2016 12:09:00 GMT</pubDate></item><item><title>IIROC Trade Resumption - NVC</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/iiroc-trade-resumption-nvc-120900534.html</link><description /><guid isPermaLink="false">yahoo_finance/1352417963</guid><pubDate>Tue, 01 Nov 2016 12:09:00 GMT</pubDate></item><item><title>Neovasc Announces Update in Litigation with CardiAQ</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/neovasc-announces-litigation-cardiaq-110000786.html</link><description>[CNW Group] - Neovasc Announces Update in Litigation with CardiAQ</description><guid isPermaLink="false">yahoo_finance/2584396219</guid><pubDate>Tue, 01 Nov 2016 11:00:00 GMT</pubDate></item></channel></rss>